“Toby is a great steward of financial integrity, bringing significant
value and global business insights. He has raised capital, completed
mergers and acquisitions (M&A) and led operating finance organizations
to support commercial activities for global biopharma businesses. We are
thrilled to add Toby to our executive team, as we focus on our
regulatory filings in the U.S. and internationally and enter our next
critical phase of growth,” said President and Chief Executive Officer
Mr. Schilke is a proven leader in the global biopharma arena, with 20
years of experience. He joins Revance from
Mr. Schilke holds a Master of Business Administration from
“I am honored and incredibly excited to join Revance at this pivotal moment in its growth. RT002 is a unique and versatile neuromodulator with differentiated clinical data and Dan has assembled a stellar organization to bring it to market,” said Mr. Schilke. “I look forward to working with the team and stakeholders to build Revance into a leader in the field.”
In connection with Mr. Schilke 's employment agreement as chief
financial officer of Revance, the Compensation Committee of Revance’s
Board of Directors has approved the grant of inducement awards pursuant
to Rule 5635(c)(4) of the NASDAQ Listing Rules. Mr. Schilke’s inducement
awards consist of a stock option to purchase 100,000 shares of Revance
common stock and 18,000 shares of restricted Revance common stock. Mr.
Schilke's options will vest over a period of four years, with 25%
vesting on
About
“Revance Therapeutics” and the Revance logo are registered trademarks of
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to current and anticipated future clinical development of our investigational drug product candidates; statements about our business strategy, timeline and other goals and market for our anticipated products, plans and prospects; and potential benefits of our drug product candidates and our technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from our
expectations. These risks and uncertainties include, but are not limited
to: the outcome, cost, and timing of our product development activities
and clinical trials; the uncertain clinical development process,
including the risk that clinical trials may not have an effective design
or generate positive results; our ability to obtain and maintain
regulatory approval of our drug product candidates; our ability to
obtain funding for our operations; our plans to research, develop, and
commercialize our drug product candidates; our ability to achieve market
acceptance of our drug product candidates; unanticipated costs or delays
in research, development, and commercialization efforts; the
applicability of clinical study results to actual outcomes; the size and
growth potential of the markets for our drug product candidates; our
ability to successfully commercialize our drug product candidates and
the timing of commercialization activities; the rate and degree of
market acceptance of our drug product candidates; our ability to develop
sales and marketing capabilities; the accuracy of our estimates
regarding expenses, future revenues, capital requirements and needs for
financing; our ability to continue obtaining and maintaining
intellectual property protection for our drug product candidates; and
other risks. Detailed information regarding factors that may cause
actual results to differ materially from the results expressed or
implied by statements in this press release may be found in Revance's
periodic filings with the Securities and Exchange Commission (the
"SEC"), including factors described in the section entitled "Risk
Factors" of our quarterly report on Form 10-Q filed on
View source version on businesswire.com: https://www.businesswire.com/news/home/20181011005236/en/
Source:
INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert
(714)
325-3584
jherbert@revance.com
or
Burns
McClellan, Inc.:
Ami Bavishi
(212) 213-0006
abavishi@burnsmc.com
or
MEDIA
General
Media:
TOGORUN:
Mariann Caprino
(917) 242-1087
m.caprino@togorun.com
or
Trade
Media:
Nadine Tosk
(504) 453-8344
nadinepr@gmail.com